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maceutical health care standards and outcomes. Without close monitoring of key
health care indicators and outcomes, volume (prescription) limitations introduced
by the recent Healthcare Reform can have adverse and inevitable long term impact.
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THE PHARMACIST’S PERCEPTION OF THE SPLITTING EXTENDED RELEASE AND
ENTERIC-COATED FORMULATION DRUGS
Jang HM, Lee EK
Sookmyung Women’s University, Seoul, South Korea
OBJECTIVES: Extended release and enteric coated formulations make up 7.8% of all
drugs, and the most frequently used drug is an agent affecting circulatory, digestive
system. The objective of this study is to analyze of extended release and enteric
coated drugs on pharmaceutical reimbursement item list in Korea and evaluate the
dispensing of extended release and enteric coated drugs, which is enforced by the
National Health Insurance. METHODS: The analysis used a questionnaires survey
for 169 pharmacists in the hospital pharmacy and community pharmacy(Response
rate: 73.8%). The questions include; prescribing change after enforcement by Na-
tional Health Insurance, prescription correction, change of pharmacy works, ex-
pansion of the range of enforcement, provision of information and prescribing
error prevention. The statistics methods use Chi-square, AVOVA, t-test, McNemar
test by STATA/SE10.(p0.05). RESULTS: Of extended release and enteric coated
formulations, 33.9% were not available in other dosage forms. After enforcement
by National Health Insurance, the rate of splitting and crushing of extended release
and enteric coated drugs decreased, but pharmacies in tertiary care hospitals had
increased workload because of prescription corrections. Prescription was not
changed, because patients take medicines for a long time. Most of pharmacists
agreed on the expansion of drug range, but 65.7% of pharmacists wanted the en-
forcement only for hospitals. When pharmacists corrected their prescribing error,
the biggest problem was a lack of other dosage forms. To prevent extended release
and enteric coated from splitting and crushing, pharmacists want in the following
ways; prescribing code prohibits into order computer system, warnings and alerts
on prescribing, developing many other dosage forms. CONCLUSIONS: What is
needed are medication-use system improvements and the creation of lists with
suggestions for alternative products on the formulary. Also, pharmaceutical com-
panies should make an effort to develop other dosage forms.
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OBJECTIVES: Irrational prescribing of injections is widespread in Iran. According to
statistics of National Committee of Rational Drug Use (NCRUD), based on data from
insured prescriptions, more than 40% of prescriptions have at least one injection in
which injectable dosage form of dexamethasone is on the top of list. The aim of this
study is to describe the prescribing pattern of dexamethasone in general practitio-
ners’ prescriptions from 2006 to 2009. METHODS: A retrospective cross-sectional
study was done on insured prescription during 4 years. All insured prescriptions
which were collected in special software called Rx Analyst during the study period
in the NCRUD were reviewed for prescriptions included injectable dosage form of
dexamethasone. RESULTS: A total of 150,630,381 Prescriptions were reviewed in
which 73,808,887 were detected to be included at least one injection. Among pre-
scriptions with injections, there were more than 30 percent of prescriptions which
had at least one injection form of dexamethasone making it the first prescribed
medicine by general practitioner. An overall increasing linear trend in prescribing
pattern of injectable dosage form of dexamethasone was evident over the obser-
vation period. The percent of general practitioners’ prescriptions which had inject-
able dosage form of dexamethasone is 15.46 in 2006, 15.93 in 2007, 16.64 in 2008 and
16.94 in 2009. CONCLUSIONS: Irrational prescribing pattern of dexamethasone
injection is obviously determined according to the results of this study. It seems
that general practitioners are trying to substitute pain relievers’ drugs by injectable
dosage form of dexamethasone. A multi-interventional policy is needed to correct
the pattern use of dexamethasone.
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PILL BURDEN IN SOUTH AFRICAN PATIENTS WITH MULTIPLE RISK FACTORS
FOR METABOLIC SYNDROME
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OBJECTIVES:Metabolic syndrome is a cluster of several common metabolic distur-
bances, including inter alia hypertension, hyperglycaemia and dyslipidaemia. Each
of these risk factors requires multiple agents to reach desired therapeutic goals.
The aim was to determine the average pill burden level in patients treated concur-
rently with antidiabetic-, antihypertensive- and lipid-lowering agents. METHODS:
A retrospective, quantitative drug utilization review was conducted utilizing na-
tional medicine claims data obtained from a South African Pharmaceutical Benefit
Management company for the period of January 1, 2008 to December 31, 2008.
Average pill burden (AvPB) was calculated as the average number of tablets re-
ceived per prescription over the study period divided by the number of days med-
ication was supplied for. Combination products were counted once. As-needed-
medication and other chronic medication were excluded from the analysis. Data
for 17 866 patients were analysed using the SAS for Windows 9.1® programme.
RESULTS: Patients had an overall AvPB of 2.71.20 per prescription, with a rate of
2.81.21 among males (n 9 632) vs. 2.61.18 for females (n 8 234). Patients aged
0-15 years (n  2) had an AvPB of 1.20.30 per prescription, vs. 2.31.49 for those
aged 16-30 years (n 53), 2.61.11 for those 31-45 years (n 992), 2.81.18 for those
46-60 years (n  5 768), 2.81.23 for those 61-75 years (n  7 641) and 2.51.17 for
those older than 75 years (n 3 410). CONCLUSIONS:Metabolic syndrome patients
are prescribed multiple drug therapies. Our results show that the average pill bur-
den among private health care South African patients receiving antidiabetic-, an-
tihypertensive- and lipid-lowering agents concurrently were the highest among
men, and increased progressively with age to peak in those aged 61-75 years. Fur-
ther studies are necessary to determine the influence of pill burden on adherence,
drug interactions and treatment cost.
Health Care Use & Policy Studies – Equity And Access
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OBJECTIVES: Hospice service appeared in 1991, when Hungarian Hospice Founda-
tion was established. More and more hospice institutions were started their works
in this period, which type was home care, palliative hospital ward and complex,
which provides both of them. In our study we are analyzing the spatial distribution
of Hungarian hospice service.METHODS: In 2008, number and activities of hospice
service was examined and we have been drawn attention for financial data by our
survey with data of National Health Insurance Fund and Central Statistics Office.
We analyzed the county and regional distribution of hospice services. RESULTS:
Thirty hospice care providers were reimbursed by the National Health Insurance
Fund Administration in 2008. The total number of nursing days were 53,113 in
Hungary. The number of nursing days per 10,000 populations showed a significant
difference across the regions with a national average of 52.88 days: Western Trans-
danubian Region (86.64), Northern-Hungarian Region (83.84), Southern-Transdu-
bian Region (81.28), Southern Great-Plain Region (77.31), Central-Transdanubian
Region (59.62), Central Hungarian Region (32.23) and Northern Great-Plan Region
(1.68). At county level we found similar within country differences with the highest
value in Nógrád county (190.83 days/per 10,000 population) and the lowest in
county Jász-Nagykun-Szolnok and Fejér ( 7 days/per 10,000 population).
CONCLUSIONS: The regional differences in hospice care are high among Hungar-
ian regions and counties. A further analysis is required to explore the reasons
behind these huge differences.
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OBJECTIVES: To explore the attitudes of the general public towards the principle of
QALY maximization in pricing and reimbursement decision-making process in
Poland. METHODS: Cross sectional survey of a random representative sample of
1000 residents was preformed. Face-to-face interviews were conducted using a
structured questionnaire. The final format of the questionnaire included refine-
ments based on a pilot survey. Respondents rated statements concerning attitudes
to equity on a Likert scale. Two hypothetical experiments were designed to elicit
preferences for QALY maximization. In the first experiment, responders had to
allocate a given limited budget to 400 patients with non-fatal disease, 100 patients
with fatal disease, or a combination of patients with fatal and non-fatal disease.
The QALY gain per patient was assumed the same for both groups. In the second
experiment, responders prioritized a given treatment to either 100 patients with
eight years or 100 patients with two years of baseline life expectancy. The survival
gain per patient resulting from the new treatment was eight years for first group
and varied from two to eight years for the second group. RESULTS: The study
indicated strong support for the statements about equity (42% agreed and 44%
strongly agreed). In the first experiment, 75% chose to allocate budget to both
groups of which 50% preferred equal distribution. In the second experiment, if
survival gain per patient was equal for both groups, 57% chose treatment for group
with shorter baseline life expectancy. If survival gain per patient was larger for
group with longer baseline life expectancy, 49% still chose treatment for group with
shorter life expectancy. CONCLUSIONS: General support for statements express-
ing equity was confirmed by two experiments. Instead of QALY maximization, a
significant group of responders took into consideration needs of both patients’
groups irrespective of costs and disease severity irrespective of QALY gain.
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OBJECTIVES: Research has shown that Medicaid enrollees in the USA are the most
frequent users of the Emergency Department (ED) services. Several studies have
demonstrated that a high proportion of the ED visits could be avoided. The purpose
of this analysis is to examine the demographic and health system delivery charac-
teristics that are associated with avoidable ED visits (AEDV) among a high risk, high
cost Medicaid population between 2008 and 2009. METHODS: One year claims
dataset of a sample of high cost, high risk Medicaid enrollees in Houston, Texas was
used for the analysis. This was design following the Andersen-Aday theoretical
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framework for studying access to health care. ED visits were classified into avoid-
able or not using the New York University algorithm. Patient complexity was mea-
sured using the Chronic Illness Intensity Index (CI3), an index used to measure
need of case management intensity. We performed logistic regression models to
test for significant association between AEDV, and population at risk and health
care delivery characteristics. RESULTS: We found that 69% (179) of our population
had an ED visits during 2008-2009. Of these visits, 60% were classified as AEDV. The
analysis showed that women were 33% less likely to have an AEDV per month. Age
was negatively associated, with younger patients being more likely to have AEDV.
More complex patients were 6.6% more likely to have an AEDV. For every extra
physician a patient visited, the probability of having an AEDV per month increased
by 2.4%, however this was not significant (p 0.06) at 95% confidence interval.
CONCLUSIONS: Among high cost, high risk Medicaid patients there are certain
patient characteristics that can allow us to identify those at higher risk of having an
AEDV. This information could be use to identify groups that would benefit from
interventions to reduce ED utilization.
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OBJECTIVES: Formal systems of health technology appraisal (HTA) can directly
inform resource allocation in healthcare systems and have contributed to the eq-
uitable and efficient allocation of such resources. To engender and maintain sup-
port from a wide range of stakeholders it is important that HTA systems are seen a
socially just, particularly in the face of contentious decisions. Effective appeals
processes, internal or judicial, can have an important role in meeting this goal,
enabling stakeholders to directly question the evidence considered, its interpreta-
tion, and the decision making process. We conducted an empirical review of the
results of all appeals made to the National Institute for Clinical Excellence (NICE)
between the years 2000 and 2010, and consider whether NICE fulfills these
requirements.METHODS:A retrospective review of all completed NICE technology
appraisals published between March 2000 and October 2010 was conducted. Each
technology appraisal was investigated for appeals. Published appeals were then
categorized by appeal substance, stakeholder, and outcome. The results were pre-
sented as absolute numbers and proportions of overall responses. RESULTS: In this
study 29% of appraisals resulted in a published appeal of which 41% were upheld.
The most common ground for an appeal, 59% of total, was perversity of the deci-
sion, the main substance for those appeals was misinterpretation of the clinical or
cost-effectiveness evidence. By proportion of appeals upheld the most successful
appeal point was that the HTA did not meet the scope or was deemed to be ineq-
uitable. Appeals involving a professional body or patient group were also more
likely to be successful. CONCLUSIONS: Examination of appeals to NICE would sug-
gest that a socially just and effective appeals process is in place. Decisions are
reversible and transparent and stakeholders can both participate in and question
the decision process.
Health Care Use & Policy Studies – Formulary Development
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OBJECTIVES: Over the last decade, specialist pharmacists across Europe have seen
an emergent role in many areas of the healthcare pathway. This research exam-
ined four key domains - clinical, policy, education and research - of influence of
specialist pharmacists with goal of understanding how they can impact market
access of drugs.METHODS: Structured interviews with 25 specialist oncology phar-
macists from EU5 exploring various aspects within the four identified domains of
influence. RESULTS: A selection of the most important roles of the specialist phar-
macist by domain is presented below: Clinical: 1) Coordinate safe and timely ad-
ministration of drugs and supportive treatment; 2) Coordinate outpatient support-
ive care focusing on management of symptoms; and 3) Help develop treatment
guidelines to ensure optimal use of supportive care medications. Policy: 1) Provide
formulary review for new drugs, and 2) Facilitate reimbursement for a more effi-
cient practice. Education: 1) Educate patients and members of the HC team about
drugs and their expected side effects and management, and 2) Educate members of
the public about prevention strategies and recommendation for screening and
early detection. Research: 1) Conduct internal treatment protocol audits to opti-
mise patient care pathway, and 2) Participate in institutional review board for
approval of clinical trials as well as scientific review and monitoring committees.
CONCLUSIONS: A cornerstone of market access is identification of important
stakeholders within a health care economy with the goal of understanding the
roles they play in the care pathway. The specialist pharmacist is an often over-
looked, but increasingly important stakeholder in the European health care sys-
tem. The multitude of roles played by the specialist pharmacist is in itself evidence
of increasing importance of the role. Pharmaceutical companies will need to en-
gage more closely with specialist pharmacists to ensure better patient outcomes
through appropriate use of drugs leading ultimately to increased market access.
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CENTRALIZED DRUG ASSESSMENT IN CATALONIA: WHERE WE HAVE GONE SO
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OBJECTIVES: The Committee for the Assessment of Hospital Drugs, led by the
Catalan Agency of Health Information Assessment and Quality, has provided evi-
dence-based information to regional health care decision-makers in Catalonia
about the added therapeutic value (ATV) of centralized approved drugs fit into the
orphan or advanced therapies category or have conditional approval or were ap-
proved in exceptional circumstances. This study describes the committee’s activity
since its creation.METHODS: Systematic reviews of efficacy, safety and cost-effec-
tiveness are conducted upon request from the Pharmacy Directorate and results
are appraised by expert panels. RESULTS: A total of 22 drugs (24 indications) for an
estimated population of 1.100 patients have been assessed. Most drugs were
granted approval for two major therapeutic areas: onco/hematological (41%) and
metabolic diseases (32%). Orphan designation had been given to 70% of all indica-
tions. Only 8 indications were given positive opinion based on 2 clinical trials. Most
pivotal studies were randomized phase III trials and were considered to have mod-
erate (63%) to high (25%) risk of bias. Placebo was the most frequent comparator in
controlled studies but was only considered appropriate in half. Primary endpoint
was a surrogate/intermediate endpoint in 94% of studies. Relevance of efficacy
results was difficult to interpret due to design flaws, small samples and short-term
follow-ups. Scarce or no data on effectiveness was available. Information on com-
parative safety was also scant and limited by short-term follow-ups. At time of
assessment cost-effectiveness data was missing in 66% of the indications. Re-
ported base-case incremental cost-effectiveness ratios from manufacturers ranged
from 16.000-565.000£/QALY. CONCLUSIONS: Defining ATV of new entities at the
time of introduction proved a challenge because of low quality studies and lack of
information about relative effectiveness. Registers and/or risk-sharing schemes
may be an alternative to gather more information new about drugs and establish
their real ATV while facilitating access.
Health Care Use & Policy Studies – Health Care Costs & Management
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OBJECTIVES: Urban green spaces (UGS) are thought to impact on health and well-
being. Cost-effectiveness analysis (CEA) can help to determine if provision or in-
terventional use of urban green spaces can contribute to population health in a cost
effective manner. This mapping review aims to characterise the study designs,
independent variables, outcomes and outcome measures reported in the
literature. METHODS: Key health and medical databases were searched. Studies of
any design (except reviews) which attempted to value the health and wellbeing
effects of UGS were included. One reviewer selected studies with a proportion
checked by a second and third reviewer. Data were extracted from abstracts using
a standardised form. Data were coded using a grounded theory approach and syn-
thesised in graphical and tabular form. RESULTS: A total of 189 citations were
included. The most common study design was cross sectional regression analyses;
there were only three randomised controlled trials. Many putative independent
variables were identified, including psychological, socio-economic, environmental
and interventional variables. Settings and populations also varied. Outcomes
coded as health behaviours included physical activity, visit frequency, nutrition
and social interaction; those coded as health outcomes included general health,
mental health, quality of life, wellbeing, mortality, obesity and cardiovascular in-
dices amongst others. Outcome measures were generally not compatible with CEA.
Amongst 61 economic studies, the most common study type was hedonic pricing.
Only one limited CEA analysis was identified. CONCLUSIONS: Few randomised
studies have been performed and available evidence would not allow a traditional
CEA. Existing trials have limited external validity according to criteria normally
used in health contexts. Current evidence may better lend itself to logic modelling,
as the causal pathways are long and complex and green space is likely to act at both
the individual and population level. To aid CEA, future research should carefully
choose study design, outcomes and outcome measures.
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ESTIMATION OF INCREASES IN DIRECT MEDICAL EXPENDITURES ASSOCIATED
WITH MEDICATION NONADHERENCE AND POTENTIAL SAVINGS FROM
INCREASED ADHERENCE
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OBJECTIVES: We estimated increases in medical expenditures due to medication
nonadherence and potential savings of increasing adherence for members of a
prescription-drug benefit plan taking medications in four drug therapy classes
(TCs).METHODS:We used data from the Medical Expenditure Panel Survey (MEPS)
to estimate functional relationships between adherence and resource utilization
for patients taking medications in four TCs. Resource use included all-cause and
disease-specific annual hospitalizations and emergency room (ER) visits. TCs in-
cluded depression, diabetes, high blood cholesterol (cholesterol), and high blood
pressure or heart disease (heart). Adherence was estimated using the medication
possession ratio (MPR). MPR less than 80% was considered nonadherence. Average
medication expenditures, by TC, was obtained from a large prescription-drug da-
tabase. Expenditures per hospitalization and ER visit were estimated from MEPS.
Unit costs and functional relationships between adherence and resource use were
applied to estimate annual resource use and medication expenditure. Increased
expenditures due to nonadherence were estimated for nonadherent patients ver-
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